Stock HLUN B H. LUNDBECK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 15:59:54 17/05/2024 BST 		5-day change 1st Jan Change
37.4 DKK +0.43% Intraday chart for H. Lundbeck A/S +8.16% +14.16%
05-15 H LUNDBECK : Q1 beat adds momentum to the recent share price rally Alphavalue
05-15 Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 25,433 31,719 36,108 - -
Enterprise Value (EV) 1 27,464 31,008 31,638 28,064 24,023
P/E ratio 13.5 x 14.2 x 12.2 x 10.5 x 9.48 x
Yield 2.23% 2.14% 2.39% 2.75% 3.23%
Capitalization / Revenue 1.39 x 1.59 x 1.71 x 1.63 x 1.58 x
EV / Revenue 1.51 x 1.56 x 1.5 x 1.27 x 1.05 x
EV / EBITDA 5.89 x 5.49 x 5.25 x 4.31 x 3.45 x
EV / FCF 10.2 x 8.66 x 7.26 x 6.05 x 4.75 x
FCF Yield 9.83% 11.5% 13.8% 16.5% 21%
Price to Book 1.24 x 1.47 x 1.5 x 1.35 x 1.2 x
Nbr of stocks (in thousands) 992,840 992,840 992,011 - -
Reference price 2 26.05 32.76 37.40 37.40 37.40
Announcement Date 07/02/23 07/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 17,036 17,672 16,299 18,246 19,912 21,089 22,133 22,892
EBITDA 1 4,823 4,783 3,720 4,663 5,652 6,030 6,506 6,956
EBIT 1 3,608 1,990 2,010 2,852 3,195 4,024 4,960 5,566
Operating Margin 21.18% 11.26% 12.33% 15.63% 16.05% 19.08% 22.41% 24.31%
Earnings before Tax (EBT) 1 3,481 1,906 1,581 2,474 2,993 4,152 4,711 5,407
Net income 1 2,667 1,581 1,318 1,916 2,290 3,075 3,456 3,837
Net margin 15.66% 8.95% 8.09% 10.5% 11.5% 14.58% 15.61% 16.76%
EPS 2 - - - 1.930 2.310 3.059 3.548 3.945
Free Cash Flow 1 2,169 3,360 1,662 2,699 3,579 4,361 4,637 5,055
FCF margin 12.73% 19.01% 10.2% 14.79% 17.97% 20.68% 20.95% 22.08%
FCF Conversion (EBITDA) 44.97% 70.25% 44.68% 57.88% 63.32% 72.32% 71.28% 72.67%
FCF Conversion (Net income) 81.33% 212.52% 126.1% 140.87% 156.29% 141.82% 134.19% 131.72%
Dividend per Share 2 - - - 0.5800 0.7000 0.8944 1.029 1.210
Announcement Date 06/02/20 04/02/21 09/02/22 07/02/23 07/02/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,053 4,372 4,475 4,719 4,680 5,044 4,938 4,952 4,978 5,288 5,257 5,360 5,327 - -
EBITDA 1 440 1,290 1,049 1,414 910 1,845 1,493 1,521 793 1,746 1,585 1,672 1,221 - -
EBIT 1 6 875 622 952 403 1,233 840 891 231 1,278 1,470 1,556 1,090 - -
Operating Margin 0.15% 20.01% 13.9% 20.17% 8.61% 24.44% 17.01% 17.99% 4.64% 24.17% 27.96% 29.03% 20.46% - -
Earnings before Tax (EBT) 1 -112 528 647 882 417 1,150 785 883 175 1,307 1,048 1,111 852 - -
Net income 1 -2 412 505 688 311 880 600 676 134 1,006 996 800.7 732.1 - -
Net margin -0.05% 9.42% 11.28% 14.58% 6.65% 17.45% 12.15% 13.65% 2.69% 19.02% 18.94% 14.94% 13.74% - -
EPS 2 - - 0.5100 0.6900 0.3100 0.8900 0.6000 0.6800 0.1400 1.010 0.7977 0.8348 0.5226 1.200 1.410
Dividend per Share 2 - - - - 0.5800 - - - 0.7000 - - - 0.4803 - -
Announcement Date 09/02/22 11/05/22 17/08/22 09/11/22 07/02/23 10/05/23 16/08/23 08/11/23 07/02/24 15/05/24 - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,625 3,966 3,043 2,031 - - - -
Net Cash position 1 - - - - 711 4,469 8,044 12,085
Leverage (Debt/EBITDA) 1.374 x 0.8292 x 0.818 x 0.4356 x - - - -
Free Cash Flow 1 2,169 3,360 1,662 2,699 3,579 4,361 4,637 5,055
ROE (net income / shareholders' equity) 26.8% 9.37% 14.2% 16.4% 10.7% 16.4% 15.7% 15.8%
ROA (Net income/ Total Assets) 13.2% 4.4% 7.07% 8.87% 6.12% 7.77% 8.12% 8.2%
Assets 1 20,266 35,893 18,647 21,606 37,429 39,596 42,561 46,796
Book Value Per Share 2 - - - 20.90 22.20 24.90 27.80 31.10
Cash Flow per Share 2 - - - 3.540 4.110 4.720 5.210 5.270
Capex 1 440 477 610 820 501 450 476 492
Capex / Sales 2.58% 2.7% 3.74% 4.49% 2.52% 2.14% 2.15% 2.15%
Announcement Date 06/02/20 04/02/21 09/02/22 07/02/23 07/02/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for H. Lundbeck A/S

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.4 DKK
Average target price
39.96 DKK
Spread / Average Target
+6.84%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
H. LUNDBECK A/S Stock H. Lundbeck A/S
+14.16% 5.26B
MCKESSON CORPORATION Stock McKesson Corporation
+21.93% 73.38B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.71% 24.13B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+7.33% 8.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+10.34% 8.59B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-19.80% 8.06B
EBOS GROUP LIMITED Stock EBOS Group Limited
-0.03% 4.21B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+12.70% 4.17B
GALENICA AG Stock Galenica AG
-2.54% 3.89B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+24.00% 3.71B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. Financials H. Lundbeck A/S